HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:
Sign In to gain access to subscriptions and/or personal tools.

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Request Reprints Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Tuerck, D. Articles by Sedek, G. Search for Related Content PubMed PubMed Citation Articles by Tuerck, D. Articles by Sedek, G. Social Bookmarking                   What's this?

Dose-Proportional Pharmacokinetics of d-threo-Methylphenidate After a Repeated-Action Release Dosage Form

From Novartis Pharma AG, Exploratory Development, Drug Metabolism and Pharmacokinetics, Basel, Switzerland (Dr Tuerck, Dr Appel-Dingemanse); Novartis Pharmaceuticals Inc, Exploratory Clinical Development, East Hanover, New Jersey (Dr Maboudian, Dr Sedek); Novartis Pharma AG, Exploratory Development, Bioanalytics, Rueil-Malmaison, France (Mrs Pommier); and Novartis Pharmaceuticals Inc, Biostatistics and Reporting, East Hanover, New Jersey (Dr Wang).

A bimodal extended-release formulation of d-methylphenidate (d-MPH) has been developed to enable fast onset of action and once-daily administration in patients with attention deficit hyperactivity disorder. The authors studied the dose proportionality of extended-release d-MPH pharmacokinetics. Twenty-five healthy adult volunteers received 5, 10, 20, 30, and 40 mg d-MPH in a crossover study with 7 days between doses. All doses were well tolerated. Dose proportionality was shown for all dose-dependent pharmacokinetic parameters. Geometric means (%gCV) for the first C_max peak, C_max0-4, were 3.25 (29.0%), 6.05 (27.1%), 12.6 (31.9%), 18.5 (31.9%), and 25.2 ng/mL (29.3%) for d-MPH 5, 10, 20, 30, and 40 mg, respectively. Geometric means (%gCV) for C_max4-10 were 3.18 (27.5%), 5.84 (27.7%), 12.5 (31.7%), 17.7 (31.6%), and 23.6 ng/mL (29.0%), respectively. Geometric means for AUC_0- were 24.3 (30.7%), 45.9 (30.2%), 96.4 (35.5%), 144 (33.3%), and 195 ng • h/mL (30.9%), respectively. The pharmacokinetics of once-daily extended-release d-MPH are proportional to the dose.

Key Words: d-MPH • dose proportionality • pharmacokinetics • extended release • human

Address for reprints: Dr Silke Appel-Dingemanse, Global Head DMPK PK Neurosciences, WSJ-210.4, Novartis Pharma AG, Lichtstrasse 35, CH-4002 Basel, Switzerland.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?